

Supporting Information

Development of a non-invasive KIM-1-based live-imaging technique in the context of a drug-induced kidney-injury mouse model

Tae-Jun Kwon^{a†}, Eunseo Jang^{a†}, Da-sol Lee^a, Md. Enamul Haque^c, Rang-Woon Park^c, Byungheon Lee^c, Sang Bong Lee^d, Dongkyu Kim^a, Yong-hyun Jeon^a, Kil-Soo Kim^{a,b}, Sang Kyoon Kim^{a*}

^a *Laboratory Animal Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, Korea*

^b *College of Veterinary Medicine, Kyungpook National University, Daegu, Korea*

^c *Department of Biochemistry and Cell Biology, BK21 Plus KNU Biomedical Convergence Program, CMRI, School of Medicine, Kyungpook National University, Korea*

^d *Korea Institute of Medical Microrobotics (KIMIRo), Gwangju, Korea*

† Both authors contributed equally to this work

*** Address correspondence to:**

Sang Kyoon Kim

80 Cheombok-ro, Dong-gu, Daegu, Korea (41061),

E-mail: ksk1420@dgmif.re.kr

Figure S1




Figure S1. Blood urea nitrogen (BUN) levels in the cisplatin-induced kidney-injury model

Nude mice received cisplatin (3 or 5 mg/kg) intraperitoneally, for five consecutive days. The control group received PBS. BUN levels were quantified and are represented as mean±SD.

* $p \leq 0.05$ *** $p \leq 0.001$.

Figure S2




Figure S2. High-dose (20 mg/kg) cisplatin treatment induces high renal and circulatory levels of KIM-1 time dependently Animals were treated with a single high dose of cisplatin (20 mg/kg) intravenously, and euthanized at different time points. (A) KIM-1 levels were quantified using western blot analysis on the samples from the kidney and serum collected at 24, 48, 72, and 96 h after cisplatin treatment. (B) Kidney sections were stained using anti-Kim-1 antibody (red) and DAPI (blue) to assess KIM-1 expression through immunofluorescence.

Figure S2

Figure S3




Figure S3. Labeled-CNRRRA peptide for imaging in mice with cisplatin-induced acute toxicity Animals were treated with a single high dose of cisplatin (20 mg/kg) intravenously. The CNRRRA labeled peptide was administered intravenously 72 h later, and animals were imaged after one day. (A) Representative live imaging data (B) *Ex vivo* image and total radiation efficiency (C) BUN level after cisplatin injection of 20 mg/kg (1~4 days)

Figure S3

Figure S4




Figure S4. Stability of CNRRRA peptide in mouse plasma. The peptide was analyzed using Mass Q-tof (Waters Corp. USA). The mass area of intact peptide was calculated after incubation for 0, 1, 4, 6, 24, 30 h in mouse plasma.

MS Condition: Aquinity UPLC BEH C18 column,

MS negative sensitivity mode

Flow: 0.5 ml/min

Water/ACN isocratic

MW: 774

Figure S4